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Randomised controlled trials addressing the optimal tim-
ing of ART initiation in patients with tuberculosis are
awaited but meanwhile, data from observational cohorts
may inform policy. The decision of when to initiate
HAART is complex, involving a number of variables
including treatment tolerability, drug co-toxicities, phar-
macokinetic drug interactions and impact of polyphar-
macy on adherence. However, of over-riding importance
is mortality associated with delays in ART initiation versus
mortality associated with immune reconstitution disease
(IRD) when HAART is initiated early. Cross cohort com-
parisons are complicated by differing mortality in cohorts
from high- and low-resourced settings and differing inci-
dence of TB-associated IRD in TB patients initiating ART
in different settings. While variable rates of IRD may rep-
resent differences between cohorts; analysis is compli-
cated by variable ascertainment, and a lack of a
standardised IRD definition. The proportion of patients
reported to develop TB-associated IRD is higher and asso-
ciated mortality lower in high- compared with low-
income settings. Mortality in the first year of ART in sub-
Saharan Africa (8–26%) greatly exceeds those in Euro-
pean and North American cohorts (approximately 2–
3%), with most deaths occurring early after initiation of
treatment. The mortality associated with delay in ART ini-
tiation is therefore likely to be much higher in Africa than
in high-income countries. In South Africa, severe TB-asso-
ciated IRD tends to develop in those patients who have
high mortality risk, manifested by low CD4 cell counts
and disseminated TB. Thus, although 10.5% of a South
African cohort who developed TB-IRD died, 9.9% of TB
patients who did not develop IRD also died. Thus, devel-
opment of IRD in this study was not associated with sig-
nificant excess mortality. In low-income settings the
diagnosis of TB in HIV-infected patients is only diagnosed
after prolonged delay and yet the mortality associated
with even short delays in accessing HAART is unaccepta-
bly high. Variations in IRD frequency and associated mor-
tality indicate that the optimum timing of ART initiation
may differ between settings. In lower income countries,
the risk of mortality associated with delays in ART initia-
tion is likely to outweigh the excess mortality of TB-asso-
ciated IRD. Therefore, the optimum timing of ART
initiation may be earlier in the course of TB treatment for
patients in resource-limited settings compared to those in
high-income settings. Much interest has rightly focussed
on the optimum timing of ART in relation to TB treat-
ment. However, the potentially more important problem
of delays in the care pathway has received little attention.
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